These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 11025593)

  • 21. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
    Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
    Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
    Brusamolino E; Lazzarino M; Morra E; Inverardi D; Merante S; Castelli G; Canevari A; Dornini G; Bernasconi C
    Haematologica; 1989; 74(2):173-9. PubMed ID: 2473013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
    Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy.
    Anselmo AP; Cavalieri E; Osti FM; Cantonetti M; De Sanctis V; Alfo M; Amadori S; Enrici RM
    Anticancer Res; 2004; 24(6):4045-50. PubMed ID: 15736450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
    Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
    Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
    Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
    J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late pulmonary toxicity after treatment for Hodgkin's disease.
    Villani F; De Maria P; Bonfante V; Viviani S; Laffranchi A; Dell'oca I; Dirusso A; Zanini M
    Anticancer Res; 1997; 17(6D):4739-42. PubMed ID: 9494599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
    J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Primary treatment of early stage Hodgkin's disease].
    Molnár Z; Esik O; Illés A
    Orv Hetil; 2005 Jan; 146(2):57-61. PubMed ID: 15724953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
    Schellong G; Dörffel W; Claviez A; Körholz D; Mann G; Scheel-Walter HG; Bökkerink JP; Riepenhausen M; Lüders H; Pötter R; Rühl U;
    J Clin Oncol; 2005 Sep; 23(25):6181-9. PubMed ID: 16135485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.
    Karmiris TD; Grigoriou E; Tsantekidou M; Spanou E; Mihalakeas H; Baltadakis J; Apostolidis J; Pagoni M; Karakasis D; Bakiri M; Mitsouli C; Harhalakis N; Nikiforakis E
    Leuk Lymphoma; 2003 Sep; 44(9):1523-8. PubMed ID: 14565654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease.
    Aversa SM; Salvagno L; Sorarù M; Mazzarotto R; Boso C; Gaion F; Chiarion-Sileni V; De Franchis G; Favaretto AG; Crivellari G; Banna GL; Sotti G; Monfardini S
    Acta Haematol; 2004; 112(3):141-7. PubMed ID: 15345896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [ABVD chemotherapy for Hodgkin lymphoma at a single institute].
    Ohshima R; Motomura S; Hashimoto C; Miyazaki T; Ito S; Takasaki H; Hyo R; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Tomita N; Fujita H; Fujisawa S; Harano H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2010 Dec; 51(12):1756-61. PubMed ID: 21258185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.
    Zinzani PL; Magagnoli M; Frezza G; Barbieri E; Gherlinzoni F; Galuppi A; Bendandi M; Merla E; Albertini P; Babini L; Tura S
    Leuk Lymphoma; 1999 Feb; 32(5-6):553-9. PubMed ID: 10048428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
    Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.